Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and Nivolumab in Hepatocellular Carcinoma
NCT03781960Phase 2Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Jul 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in hepatocellular carcinoma (HCC), sponsored by Abramson Cancer Center. Started Jul 2019; status: terminated.
02
Drugs
abemaciclib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03781960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781960.